Janssen Research & Development
3210 Merryfield Row
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
130 articles about Janssen Research & Development
Janssen Research & Development To Showcase Growing Body Of Data At 2014 American Society of Clinical Oncology Annual Meeting
Janssen Research & Development Submits Supplemental New Drug Application To FDA For OLYSIO (Simeprevir) For Once-Daily Use In Combination With Sofosbuvir For 12 Weeks For The Treatment Of Adult Patients With Genotype 1 Chronic Hepatitis C
Final Data From The Phase 2 COSMOS Study Of Janssen Research & Development's Once-Daily Simeprevir In Combination With Sofosbuvir Presented At The International Liver Congress 2014 Of The European Association For The Study Of The Liver (EASL)
Janssen Research & Development Release: Supplemental New Drug Application For IMBRUVICA (ibrutinib) Submitted To The U.S. FDA
Janssen Research & Development Submits New Drug Application To FDA For A Fixed-Dose Combination Tablet Of HIV-1 Medicine Darunavir With Cobicistat As Part Of Combination HIV Therapy
Johnson & Johnson's Janssen Research & Development Test of Schizophrenia Treatment Shows Positive Results
Novozymes Biopharma Announces Collaboration With Janssen Research & Development To Evaluate Proprietary VELTIS® Half-Life Extension Technology
Janssen Research & Development Initiates CREDENCE Study In Patients With Type 2 Diabetes And Diabetic Nephropathy
Janssen Research & Development Release: Independent Data Monitoring Committee Recommends Early Stopping Of Phase 3 Study Of Ibrutinib In Relapsed/Refractory CLL/SLL Patients Based On A Planned Interim Analysis
Janssen Research & Development Release: FDA Issues Complete Response Letter For Canagliflozin/Metformin Fixed-Dose Combination Therapy For Type 2 Diabetes
Janssen Research & Development Release: Ibrutinib Data Published In The Lancet Oncology Suggest A Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
Janssen Research & Development Release: New Two-year Results Show SIMPONI® ARIA™ (golimumab) for Infusion Inhibited Radiographic Progression in Patients With Active Rheumatoid Arthritis
Janssen Research & Development Release: New STELARA® Data Show Inhibition of Joint Destruction in Patients With Active Psoriatic Arthritis
Janssen Research & Development Release: FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
Janssen Research & Development Release: Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for Study of Liver Diseases
Janssen Research & Development Release: Simultaneous Applications Submitted to FDA and European Medicines Agency for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
Janssen Research & Development Release: Prothrombin Complex Concentrates Can Reverse Blood Thinning Effects of XARELTO® (rivaroxaban)
Janssen Research & Development Release: Studies Reinforce INVOKANA™ (canagliflozin) (300mg) Provides Greater Improvements in Blood Glucose Than Sitagliptin (100 mg) or Glimepiride (6 or 8 mg) in Adults With Type 2 Diabetes